New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology annual meeting, including: Beyondspring, Coimmune, Geron, JW, Novartis, Oncolytic, Oncternal, Oric, Oryzon, Ose, Pfizer, Poseida, Precigen, Rheos, Roche, Rocket, Sangamo, Sanofi, Seagen, Secura, Sierra, Syndax, Talaris, Tessa, TG, Viracta, Wugen, Xencor.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology annual meeting, including: 2seventy, Actinium, Agios, Allogene, Antegene, Apellis, Aptose, Ascentage, Atar, Bantam, Bioinvent, Daiichi, Harpoon, Iaso, Innocare, Innovent, Janssen, Karyopharm, Keros, Kymera, Lantern, Legend, Magenta, Mereo, Mustang, Nektar, Neximmune, Nextcure, Nkarta.
Two trials presented at the annual meeting of the American Society of Hematology (ASH) showed that treatment with the antithrombin inhibitor fitusiran reduced the bleeding rate in patients with severe hemophilia by roughly 90%, regardless of whether they had type A or B, and whether they had developed antibodies to recombinant clotting factors.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology annual meeting, including: Actinium, Adagene, Affimed, Agios, Allogene, Annexon, Aprea, Arcellx, Astrazeneca, Autolus, Beigene, Editas, Emmaus, Epizyme, Equillium, Fate, Freeline, Gamida, GBT, Genentech, Glycomimetics, GSK, Hutchmed, I-Mab, Imara, Kite, Kura, Sutro.
Orca Bio Inc. reported at the American Society of Hematology that cancer patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) who received its Orca-T cell therapy product achieved higher rates of survival without experiencing either relapse or chronic graft-vs.-host (GvHD) disease than those who received a conventional graft.
Core presentations at the 63rd meeting of the annual American Society of Hematology (ASH) began Saturday morning with the presentation of three studies focused on non-Hodgkin lymphomas and one on multiple myeloma (MM). Each approach used the immune system as a cancer fighter but employed different mechanisms of action. Two of them successfully used CAR T therapies as treatment.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer annual meeting, including: Harpoon, Highlight, Imcheck, Immunogenesis, Immutep, Intensity, Ionctura, Iovance, Instil, Kenjockety, Kymera, Mina, Moderna, Morphic, Nektar, Neoleukin, Nextcure, Nurix, Oncoresponse, Oncorus, Phio, Puretech, Replimune, Rubius, Scholar Rock, Second Genome, Sensei, Senti, Seven and Eight, Sotio, SQZ, Tempest, T-knife, Treadwell, Triumvira, Wugen, Xencor.
New and updated preclinical and clinical data presented by biopharma firms at The Liver Meeting of the American Association for the Study of Liver Diseases, including: 89bio, Akero, Cymabay, Intercept, Protagonist, Sagimet, Surrozen, Versantis.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer annual meeting, including: Antengene, Carisma, Celularity, CG Oncology.
RSS
